Nautilus Biotechnology Inc Stock Price, News & Analysis

Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic partnership with Abcam to enhance its reagent development capabilities. This collaboration aims to accelerate R&D by utilizing Abcam's advanced monoclonal antibody technologies. The focus will be on developing affinity binding reagents for Nautilus' proteomic analysis system, followed by large-scale manufacturing and commercialization. This partnership is seen as a significant step toward improving drug and diagnostic tool development, enhancing the overall efficacy of Nautilus’ protein analysis platform.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its third-quarter financial results for 2021, highlighting significant business developments and financial metrics. The company initiated a strategic partnership with Abcam to enhance protein detection and signed two new research collaborations with a global pharmaceutical company and UT MD Anderson Cancer Center. Financially, Nautilus recorded an operating expense of $14.6 million, a 262% increase from the previous year, and a net loss of $14.5 million. However, cash reserves stood strong at $374 million as of September 30, 2021.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report its financial results for Q3 2021 on November 2, 2021. Prior to the market open, the company will hold a webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss its results and business developments. Nautilus is focused on a single-molecule protein analysis platform aimed at revolutionizing proteomics and enhancing human health and medicine.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually at the Morgan Stanley Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET. The event will feature a presentation detailing Nautilus' innovative single-molecule protein analysis platform that quantifies the human proteome. Attendees can access a live and archived webcast through Nautilus' website. The company aims to enhance basic science research and improve therapeutic development through its advanced proteomics technology.

Nautilus Biotechnology reported its second quarter 2021 financial results, revealing significant developments since becoming publicly traded on June 10, 2021, with gross proceeds of approximately $345.5 million. The company's operating expenses surged by 215% to $10.7 million, compared to $3.4 million in Q2 2020, primarily due to increased headcount and public company costs. The net loss for the quarter was $10.7 million, up from $3.4 million year-over-year. Nautilus aims for platform commercialization by late 2023 and bolstered its team with key appointments.

Nautilus Biotechnology has appointed Karl Voss, Ph.D., as the new Vice President of Life Sciences Research and Development. With over 20 years of experience, Dr. Voss previously worked at Pacific Biosciences, where he significantly contributed to the advancement of single-molecule DNA sequencing. His expertise is expected to enhance Nautilus’ mission to transform understanding in human biology through their innovative protein analysis platform, which aims to quantify over 95% of the proteome. This appointment follows Nautilus' recent public trading debut.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced plans to report its financial results for Q2 of fiscal year 2021 on August 10, 2021, before the market opens. A webcast conference call will follow at 5:00 a.m. PT / 8:00 a.m. ET to discuss the results, business developments, and future outlook. Nautilus focuses on pioneering a single-molecule protein analysis platform to advance proteomics, aiming to enhance accessibility to proteomic data and contribute to advancements in human health and medicine.

Nautilus Biotechnology announced the appointment of Dr. Emma Lundberg to its Scientific Advisory Board, effective immediately. Lundberg is a pioneer in spatial proteomics, bringing extensive expertise in human cell biology and artificial intelligence. Her role supports Nautilus's mission to develop a single-molecule protein analysis platform aimed at quantifying the proteome. This strategic addition follows Nautilus's recent public debut, backed by $345 million raised from its business combination with Arya Sciences Acquisition Corp III, aiming to fundamentally enhance biomedical research and diagnostics.

Nautilus Biotechnology completed its business combination with Arya Sciences Acquisition Corp III on June 9, 2021, and will trade under ticker symbol NAUT on the Nasdaq beginning June 10, 2021. The deal generated $345 million in gross proceeds, comprising $145 million from Arya III's trust account and $200 million in PIPE financing. The company aims to revolutionize proteomics with its technology, which could identify over 95% of the proteome using innovative approaches. Led by CEO Sujal Patel and Chief Scientist Parag Mallick, Nautilus is focused on advancing drug development and biomedical research.